Seite - 101 - in Cancer Nanotheranostics - What Have We Learnd So Far?
Bild der Seite - 101 -
Text der Seite - 101 -
Pearsonetal. Nanoparticlebiomoleculecorona
Conflict of Interest Statement:The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construedasapotential conflictof interest.
Received: 31 August 2014; accepted: 11 November 2014; published online: 27
November2014.
Citation: Pearson RM, Juettner VV and Hong S (2014) Biomolecular corona on
nanoparticles: a survey of recent literature and its implications in targeted drug
delivery.Front.Chem.2:108.doi: 10.3389/fchem.2014.00108 Thisarticlewas submitted toChemicalEngineering,a sectionof the journalFrontiers
inChemistry.
Copyright © 2014 Pearson, Juettner and Hong. This is an open-access arti-
cle distributed under the terms of the Creative Commons Attribution License
(CCBY). The use, distribution or reproduction in other forums is permitted, pro-
vided the original author(s) or licensor are credited and that the original publi-
cation in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these
terms.
www.frontiersin.org November2014 |Volume2 |Article108 |101
Cancer Nanotheranostics
What Have We Learnd So Far?
- Titel
- Cancer Nanotheranostics
- Untertitel
- What Have We Learnd So Far?
- Autoren
- João Conde
- Pedro Viana Baptista
- Jesús M. De La Fuente
- Furong Tian
- Herausgeber
- Frontiers in Chemistry
- Datum
- 2016
- Sprache
- englisch
- Lizenz
- CC BY 4.0
- ISBN
- 978-2-88919-776-7
- Abmessungen
- 21.0 x 27.7 cm
- Seiten
- 132
- Schlagwörter
- Nanomedicine, Nanoparticles, nanomaterials, Cancer, heranostics, Immunotherapy, bioimaging, Drug delivery, Gene Therapy, Phototherapy
- Kategorien
- Naturwissenschaften Chemie